Ken Haas

Investor type:

Social media:

Available after registration.

Past investments

  • Kesios Therapeutics
  • Spruce Biosciences
  • Amarin
  • Syntaxin
  • CRISPR Therapeutics
  • Attenua
  • Broncus Technologies
  • Jasper Therapeutics
  • Synosia Therapeutics
  • X4 Pharmaceuticals
  • Kspine
  • Zogenix
  • PrimeraDx (Primera Biosystems)
  • Scorpion Therapeutics
  • Avila Therapeutics
  • Personalis
  • MD On-Line
  • GenSight Biologics
  • Dicerna Pharmaceuticals
  • Verona Pharma
  • Micromet
  • Proteon Therapeutics
  • Prosensa
  • Stanmore Implants Worldwide
  • GTx
  • Median Technologies
  • Valeritas
  • Soleno Therapeutics
  • Wilson Therapeutics
  • Chroma Therapeutics
  • Avillion
  • Hydra Biosciences
  • Algeta
  • Sientra
  • Intellikine
  • Chiasma
  • Gynesonics
  • Reneo Pharmaceuticals
  • Vera Therapeutics
  • Portola Pharmaceuticals
  • Nouscom
  • Vaxcyte
  • Lombard Medical plc
  • Labcyte
  • Pathwork Diagnostics
  • Senseonics
  • Novexel
  • Clovis Oncology
  • Atsena Therapeutics
  • Cytos
  • VirionHealth
  • Phathom Pharmaceuticals
  • Fovea Pharmaceuticals
  • Venatorx Pharmaceuticals
  • IS Pharma
  • Effector Therapeutics
  • Sonitus Medical
  • Paratek Pharmaceuticals
  • Q32 Bio
  • GammaDelta Therapeutics
  • Tizona Therapeutics
  • Oxagen
  • SFJ Pharmaceuticals
  • Avedro
  • IFM Therapeutics
  • Virion Biotherapeutics
  • Realm Therapeutics
  • Pixium Vision